Page 9 - P4304.1-V108_PS Magazine - Apr 25_Neat

This promotional advert was created by Accord Healthcare Ltd and is intended for UK Healthcare Professionals.
Varenicline Tablets

0.5mg & 1mg

PSUK is pleased to offer a 40% discount

on Sereflo pMDIs for dispensing practices

Product NHS List price 1 PSUK discount Saving

Sereflo pMDI 40% £5.99
25/125mcg £14.99

Sereflo pMDI £19.99 40% £7.99
25/250mcg

Sereflo pMDI can offer a 25mcg salmeterol with 125 or 250mcg fluticasone
combination more cost-effectively than the market-leading competitors,
Seretide® and Sirdupla® (salmeterol/fluticasone). Plus, you can take
1-3
• Initiation pack and maintenance dosing. advantage of significant additional savings with the PSUK discount.

Product Presentation
Sereflo pMDI is indicated for use in adults with asthma 18 years of age and older only. 4,5
Strength 0.5mg 0.5mg + 1mg 0.5mg + 1mg 1mg 1mg
Sereflo pMDI is indicated in the regular treatment of patients with moderate to severe asthma
Pack Size 56 25 (11+14) 53 (11+42) 28 56 where use of a combination product (long-acting β2 agonist and inhaled corticosteroid)
is appropriate:
Product Format film-coated tablet film-coated tablet film-coated tablet film-coated tablet film-coated tablet - patients not adequately controlled on a lower strength corticosteroid combination product 4,5
or
Legal Category POM POM POM POM POM - patients already adequately controlled on an inhaled corticosteroid in a mid or
high strength and a long-acting β2 agonist. 4,5
Pack Dimensions 48mmx116mm 70mmx134mm 134mmx119mm 48mmx116mm 48mmx116mm
(HxWxD) x37mm x22mm x22mm x25mm x37mm Seretide is a trademark of GSK. Sirdupla is a registered trademark of Mylan.
pMDI = pressurised metered dose inhaler.
Shelf Life 24 months 24 months 24 months 24 months 24 months
PIP Code 127-5338 127-5361 127-5379 127-5353 127-5346 Sereflo Metered Dose Inhaler (salmeterol xinafoate/fluticasone with caution in patients with severe cardiovascular disorders or heart rhythm abnormalities and in
®
propionate) patients with diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or with a predisposition to
low levels of serum potassium. Prescribers should also be aware of the risk of adrenal suppression
EAN Code 5012617003249 5012617003256 5012617003263 5012617003270 5012617003287 Prescribing Information and acute adrenal crisis which may occur in patients on prolonged treatment with high doses of
Please consult the full Summary of Product Characteristics (SmPC) before prescribing
Sereflo 25 microgram (μg) salmeterol xinafoate /125 μg or 250 μg fluticasone propionate per actuation inhaled corticosteroids. Systemic effects may occur with any inhaled corticosteroid and it is important
therefore, that the patient is reviewed regularly and the dose of inhaled corticosteroid is reduced to the
Trade Price¹ £46.40 £23.20 £56.50 £23.20 £46.40 pressurised inhalation, suspension. For both dose strengths the equivalent delivered dose per lowest dose at which effective control of asthma is maintained. Visual disturbances may be reported
actuation is 21 μg of salmeterol and the delivered fluticasone propionate is 110 μg, for 125 μg dose
strength and 220 μg, for 250 μg dose strength. INDICATIONS: For use in adults with asthma 18 years with steroid use. Patients presenting with blurred vision or other visual disturbances should be
considered for referral to an ophthalmologist. Drug Interactions: Concomitant use should be avoided
1. Accord Proposition Price List February 2025 of age and older only. Sereflo is indicated in the regular treatment of patients with moderate to severe with; non-selective and selective β blockers, ritonavir and other potent/moderate CYP3A inhibitors,
asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid) is
appropriate: patients not adequately controlled on a lower strength corticosteroid combination product unless potential benefit outweighs the risk. Particular caution is advised in acute severe asthma
as hypokalaemia may be potentiated by concomitant treatment with xanthine derivatives, steroids
Please click or scan the QR codes below to access the SPC. or patients already adequately controlled on an inhaled corticosteroid in a mid or high strength and and diuretics. See the SmPC for further information on contraindications and precautions.
a long-acting β2 agonist. POSOLOGY AND ADMINISTRATION: Patients should be instructed
in the proper use of their inhaler (see SmPC and patient information leaflet). Recommended PREGNANCY AND LACTATION: Balance risks against benefits. UNDESIRABLE EFFECTS:
doses in adults 18 years and older - Two inhalations of 25μg salmeterol and 125 μg or 250 μg Adverse events which have been associated with salmeterol/fluticasone propionate include: Very
Varenicline Tablets 0.5mg fluticasone propionate twice daily. A short-term trial of salmeterol and fluticasone propionate may be common; nasopharyngitis and headache; Common; candidiasis of the mouth and throat, pneumonia,
Varenicline Tablets 0.5mg Varenicline Tablets 1mg & 1mg (initiation pack) considered as initial maintenance therapy in adults with moderate persistent asthma for whom rapid bronchitis, hypokalaemia, throat irritation, hoarseness/dysphonia, sinusitis, contusions, muscle
cramps, traumatic fractures, arthralgia and myalgia. For other adverse events please consult the full
control of asthma is essential. In these cases, the recommended initial dose is two inhalations of 25
μg salmeterol and 50 μg fluticasone propionate twice daily. Note: Sereflo is not available in a lower SmPC. MARKETING AUTHORISATION HOLDER & PL NUMBERS: Cipla (EU) Ltd. Dixcart House,
strength product containing salmeterol 25 μg and fluticasone propionate 50 μg. Therefore, when Addlestone Road, Bourne Business Park, Addlestone, Surrey KT15 2LE. PL 36390/0237 and PL
Adverse events should be reported. initiating therapy, or when it is appropriate to titrate down to a dose below 125 μg, an alternative 36390/0238. Legal category: POM. NHS Cost 25 μg/125 μg 1x 120 dose MDI £14.99 and 25 μg/250
Reporting forms and information can be found fixed-dose combination of salmeterol and fluticasone propionate containing a lower dose of the μg 1x 120 doses MDI £19.99. Date of last revision: April 2020.
inhaled corticosteroid is required. Use of a spacer device; where required in those with difficulties in
at https://yellowcard.mhra.gov.uk coordinating actuation of the inhaler with inspiration of breath, it is recommended ONLY for higher Adverse events should be reported. Reporting forms and information can
strength Sereflo containing salmeterol 25 μg and fluticasone propionate 250 μg. Patients should
continue to use the same make of spacer device (Volumatic or the AeroChamber Plus) as switching be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard
between spacer devices can result in changes in the dose delivered to the lungs. See the SmPC
Adverse events should also be reported to for further information on initiation, titration down and spacer use. CONTRAINDICATIONS: in the Google Play or Apple App Store. Adverse events should also be
Accord-UK LTD on 01271 385257 Hypersensitivity to the active substances or to any of the excipients. SPECIAL WARNINGS AND reported Cipla (EU) Ltd on 0800 0472144, drugsafety@cipla.com
PRECAUTIONS: Sereflo should not be used to treat acute asthma symptoms for which a fast- and
or email medinfo@accord-healthcare.com short-acting bronchodilator is required. Patients should be advised to have their inhaler to be used
for relief in an acute asthma attack available at all times. Patients should not be initiated on Sereflo References.
during an exacerbation, or significantly worsening or acutely deteriorating asthma. Serious asthma- 1. Dictionary of medicines and devices (dm+d), available at https://www.nhsbsa.nhs.uk/pharmacies-gp-
related adverse events and exacerbations may occur with Sereflo. Patients should be asked to practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd (accessed August 2022).
continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen 2. British National Formulary, Medicinal forms, available at
after initiation. Treatment should not be stopped abruptly due to risk of exacerbation. Therapy should https://bnf.nice.org.uk/medicinal-forms/fluticasone-with-salmeterol.html (accessed August 2022).
be down-titrated under physician supervision. All inhaled medication containing corticosteroids 3. MIMS.co.uk (accessed August 2022).
Document Number: UK-Gen-Vare-01410 should be administered with caution in patients with active or quiescent pulmonary tuberculosis and 4. Sereflo 25 microgram/125 microgram. Summary of Product Characteristics.
5. Sereflo 25 microgram/250 microgram. Summary of Product Characteristics.
fungal, viral or other infections of the airway. Salmeterol and fluticasone propionate should be used
Date of Preparation: January 2025 August 2022 CIPSER20220021
or call us on 01904 558 350 MDS Terms Information | PS Magazine 9 9
14/03/2025 16:23:10
P4304.1-V108_PS Magazine - Apr 25.indd 9 14/03/2025 16:23:10
P4304.1-V108_PS Magazine - Apr 25.indd 9